Study of Cellular Heterogeneity in Patients With Mastocytosis

Status Not yet recruiting

Clinical Trial Summary

This study will aim to study the heterogeneity of skin-resident mast cells and of blood circulating hematopoietic progenitors in patients suffering from isolated Cutaneous Mastocytosis and from systemic Mastocytosis with skin lesions.

Clinical Trial Description

Mastocytosis is a rare disease caused by abnormal mast cell accumulation/proliferation. Its clinical features are very heterogeneous. Among adult patients, 15% present an isolated cutaneous mastocytosis (CM), while 85% of them present a systemic mastocytosis (SM) with cutaneous lesions. In addition, regardless of the diagnosis (i.e., CM or SM), it is frequent to observe mast cell-dependent symptoms of variable severity, ranging from gastrointestinal discomfort to life-threatening reactions. To date, the origin of such heterogeneous manifestations in adult patients is still elusive. Researchers hypothesize that the heterogeneity in mastocytosis symptoms might originate, at least in part, from a broad diversity of mast cell populations in patients. This study will aim to uncover heterogeneity of skin-resident mast cells and of blood circulating hematopoietic progenitors in patients suffering from isolated CM or SM with skin lesions. Patients with isolated CM and patients with SM with cutaneous involvement will be recruited from the Mastocytosis Expert Center of Toulouse. Cluster of Differentiation (CD) 45+ cells from skin biopsies and CD 34+ cells from blood will be isolated by magnetic cell sorting for scRNAseq. Bioinformatics analysis pipeline will be used in order to analyze the cellular heterogeneity of skin lesions and blood from CM and SM patients by comparing their transcriptomic signatures. Using trajectories analysis, the researchers will then deduce infer a differentiation pathway between blood progenitors and cutaneous mast cells at the patient level. Researchers will then confirm the expression of identified relevant biomarkers by highly multiplexed imaging in frozen skin biopsies from CM patients and from SM patients. ;

Study Design

Related Conditions & MeSH terms

Mastocytosis

Clinical Trial Details

NCT number	NCT06432556
Study type	Interventional
Source	University Hospital, Toulouse
Contact	Cristina Bulai Livideanu, MD
Phone	0567778138
Email	livideanu.c@chu-toulouse.fr
Status	Not yet recruiting
Phase	N/A
Start date	June 1, 2024
Completion date	June 15, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01333293` - The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients	Phase 2/Phase 3
Completed	`NCT01481909` - Study on Mastocytosis for Rupatadine Treatment	Phase 2/Phase 3
Recruiting	`NCT00044122` - Study of Factors Regulating Mast Cell Proliferation
Recruiting	`NCT06440148` - Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis
Recruiting	`NCT03340155` - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases	N/A
Not yet recruiting	`NCT05084872` - Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients	Phase 2/Phase 3
Terminated	`NCT01701843` - Cromoglicate in Mastocytosis	Phase 2
Completed	`NCT00831974` - Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis	Phase 2
Completed	`NCT00047918` - Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing	N/A
Completed	`NCT00006413` - Stem Cell Transplantation to Treat Systemic Mastocytosis	Phase 2
Completed	`NCT00050193` - Cause and Natural Course of Pediatric-Onset Mastocytosis
Completed	`NCT02620254` - Mast Cell Connect: A Registry for Patients With Mastocytosis
Completed	`NCT00255346` - Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)	Phase 2
Completed	`NCT00001356` - Characteristics of Mast Cells in Mastocytosis	N/A
Recruiting	`NCT06466889` - Mastocytosis Registry (of Zurich)
Recruiting	`NCT05186753` - (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis	Phase 2
Completed	`NCT02478957` - Treatment of Indolent Systemic Mastocytosis With PA101	Phase 2
Recruiting	`NCT02450396` - Pregnancy and Medically Assisted Conception in Rare Diseases
Completed	`NCT00038675` - Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate	N/A
Completed	`NCT00336076` - Molecular Mechanisms and Diagnosis of Mastocytosis	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study of Cellular Heterogeneity in Patients With Mastocytosis — MastCellHet

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms